Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

MeiraGTx Holdings plc. (10/2/18). "Press Release: MeiraGTx to Present at Upcoming Conferences". London & New York, NY.

Organisations Organisation MeiraGTx Holdings Plc (NASDAQ: MGTX)
  Group MeiraGTx (Group)
  Organisation 2 Chardan Capital Markets LLC
Products Product Chardan Genetic Medicines Conference 2018 New York
  Product 2 Cell & Gene Meeting on the Mesa 2018 La Jolla
Index term Index term MeiraGTx–Chardan: investor conference, 201810 supply service MeiraGTx presents at Chardan Genetic Medicines Conference in New York
Persons Person Forbes, Alexandria (MeiraGTx 201810 CEO)
  Person 2 Boothe, Kelly (W2O Group 201810 W2O pure)

MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it will present at the following conferences:

> 2018 Cell & Gene Meeting on the Mesa on Thursday, October 4, 2018 at 1:45 p.m. PT (4:45 p.m. ET) at the Estancia La Jolla Hotel & Spa in California

> Chardan 2nd Annual Genetic Medicines Conference on Tuesday, October 9, 2018 at 8:00 a.m. ET at the Westin Grand Central Hotel in New York City

Presentations will be given by MeiraGTx President and Chief Executive Officer, Alexandria Forbes, Ph.D., and will be available via live webcast from the “Events and Presentations” page of the Company’s Investors & Media section of its website at Replays of the webcast will be available for 90 days following the event.

About MeiraGTx

MeiraGTx (NASDAQ:MGTX) is a vertically integrated, clinical stage gene therapy company with four ongoing clinical programs and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications. MeiraGTx’s initial focus is on three distinct areas of unmet medical need: inherited retinal diseases, severe forms of xerostomia and neurodegenerative diseases. Though initially focusing on the eye, salivary gland and central nervous system, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.

For more information, please visit




W2O pure
Kelly Boothe, Ph.D. (415) 946-1076

Record changed: 2018-10-13


Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for MeiraGTx (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Back into Ad 650x80px

» top